Compare Stanley Black & Decker, Inc. (SWK) vs BIO-TECHNE Corp (TECH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Stanley Black & Decker, Inc. vs BIO-TECHNE Corp — how do they compare? Stanley Black & Decker, Inc. trades at $91.6 (market cap $14.17B), while BIO-TECHNE Corp trades at $72.39 (market cap $11.34B). The key difference: Stanley Black & Decker, Inc. is the larger of the two by market cap, and Stanley Black & Decker, Inc. pays the higher dividend (3.58%). Which is the better fit depends on your goals.
| SWK | TECH | |
|---|---|---|
Market Cap | $14.17B | $11.34B |
52-Week High | $104.00 | $72.48 |
52-Week Low | $62.12 | $43.31 |
Enterprise Value | $18.33B | $11.36B |
Dividend Yield | 3.58% | 0.44% |
Sector | — | Health |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Stanley Black & Decker (SWK) trades at $93.81, down 3.65% today, with a bearish technical signal despite recent earnings beats. The company shows improving fundamentals with Q2 2026 EPS of $1.57 beating expectations of $1.21, and management has raised 2026 EPS guidance to $4.60-$5.45. Recent portfolio optimization includes the sale of Excel Industries to Bad Boy Mowers, focusing on core brands. Valuation metrics appear reasonable with P/E of 22.94 and P/S of 0.93, while analyst consensus price target sits at $98.50 with 43% buy ratings.
SWK presents a mixed outlook with strong earnings momentum and cost transformation benefits offset by bearish technical indicators. The stock offers value potential with upside to analyst targets and dividend income, but faces execution risks in margin expansion and industrial demand volatility. Near-term support at $90 provides a key level to watch amid current market weakness.
Bio-Techne (TECH) trades at $72.31, down 0.17% on the day, with a neutral technical signal and mixed earnings history. The stock is near the consensus price target of $71.86, with a pending acquisition by Merck KGaA at $73.00 per share. Recent Q4 2026 revenue beat estimates, but net income margin compression from 25.09% in 2023 to 14.96% in 2026 highlights profitability challenges. Operating cash flow remains stable around $290M, supporting dividend payments.
The outlook is balanced, with upside capped by the acquisition offer but supported by solid cash flow and analyst hold ratings. Risks include shareholder litigation and integration uncertainties post-acquisition. Earnings growth in diagnostics and spatial biology segments is a key catalyst, though high P/E of 62.33 suggests elevated expectations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Stanley Black & Decker, Inc.
Stanley Black & Decker Inc is a manufacturer of hand and power tools. The company operates three business segments: tools and storage, security, and industrial. Tools and storage, the largest segment by revenue, sells hand tools and power tools to professional end-users, distributors, retail consumers, and industrial customers. Security installs electronic security systems and provides electronic security services including alarm monitoring and video surveillance. Industrial sells engineered fastening products such as stud-welding systems, blind inserts and tools, and engineered plastic and mechanical fasteners. The largest end market is the United States of America.
Read more on SWK →About BIO-TECHNE Corp
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.
Read more on TECH →
